{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:33:34Z","timestamp":1776720814346,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness generally manifests as a mild disease in young children and immunocompromised adults. It has however emerged as a significant public health threat in recent years as outbreaks have been occurring regularly, especially in the Asia\u2013Pacific. The disease can result from infections by a wide variety of human enteroviruses, particularly, Enterovirus A71 (EV-A71) has garnered more attention due to its association with severe disease in infected patients. Despite the potential to result severe neurological complications or even fatality, there is currently no effective antiviral for treatment of EV-A71 infections and the only vaccines available are restricted to distribution in China. In this study, we report the in vitro and in vivo evaluation of two candidate antiviral compounds active against EV-A71, a viral capsid inhibitor (G197) and a novel host-targeting phosphatidylinositol 4-kinase III beta inhibitor (N373) which, especially when used in combination, can significantly improve the survival and pathology of infected mice.<\/jats:p>","DOI":"10.1038\/s41598-021-89271-8","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:04:35Z","timestamp":1620295475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition"],"prefix":"10.1038","volume":"11","author":[{"given":"Yong Wah","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Keat","family":"Yam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel Jia Wen","family":"Kooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Westman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustav","family":"Arbrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin Jang Hann","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"1","key":"89271_CR1","first-page":"8","volume":"7","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012\u20132016. Emerg. Microbes Infect. 7(1), 8 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"89271_CR2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/1743-422X-8-508","volume":"8","author":"F Yang","year":"2011","unstructured":"Yang, F. et al. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol. J. 8, 508 (2011).","journal-title":"Virol. J."},{"issue":"11\u201312","key":"89271_CR3","first-page":"959","volume":"57","author":"SH Park","year":"2011","unstructured":"Park, S. H. et al. Detection and characterization of enterovirus associated with herpangina and hand, foot, and mouth disease in Seoul, Korea. Clin. Lab. 57(11\u201312), 959\u2013967 (2011).","journal-title":"Clin. Lab."},{"issue":"10","key":"89271_CR4","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/jm050033v","volume":"48","author":"CS Chang","year":"2005","unstructured":"Chang, C. S. et al. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J. Med. Chem. 48(10), 3522\u20133535 (2005).","journal-title":"J. Med. Chem."},{"issue":"3","key":"89271_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11373-007-9228-5","volume":"15","author":"TC Chen","year":"2008","unstructured":"Chen, T. C. et al. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J. Biomed. Sci. 15(3), 291\u2013300 (2008).","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"89271_CR6","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/jac\/dkw101","volume":"71","author":"JY Ho","year":"2016","unstructured":"Ho, J. Y. et al. In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71. J. Antimicrob. Chemother. 71(7), 1922\u20131932 (2016).","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"89271_CR7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/acsmedchemlett.7b00188","volume":"8","author":"P Li","year":"2017","unstructured":"Li, P. et al. Discovery of potent EV71 capsid inhibitors for treatment of HFMD. ACS Med. Chem. Lett. 8(8), 841\u2013846 (2017).","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"89271_CR8","doi-asserted-by":"crossref","first-page":"e1007760","DOI":"10.1371\/journal.ppat.1007760","volume":"15","author":"L Sun","year":"2019","unstructured":"Sun, L. et al. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 15(5), e1007760 (2019).","journal-title":"PLoS Pathog."},{"issue":"4","key":"89271_CR9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/ml2002955","volume":"3","author":"SC Feil","year":"2012","unstructured":"Feil, S. C. et al. An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus. ACS Med. Chem. Lett. 3(4), 303\u2013307 (2012).","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"89271_CR10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.43.9.2109","volume":"43","author":"DC Pevear","year":"1999","unstructured":"Pevear, D. C., Tull, T. M., Seipel, M. E. & Groarke, J. M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43(9), 2109\u20132115 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"89271_CR11","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1128\/AAC.03328-14","volume":"58","author":"A Tijsma","year":"2014","unstructured":"Tijsma, A. et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 58(11), 6990\u20136992 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"20","key":"89271_CR12","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1016\/j.bmcl.2004.07.084","volume":"14","author":"JH Chern","year":"2004","unstructured":"Chern, J. H. et al. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg. Med. Chem. Lett. 14(20), 5051\u20135056 (2004).","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"89271_CR13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/jm010536a","volume":"45","author":"KS Shia","year":"2002","unstructured":"Shia, K. S. et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors. J. Med. Chem. 45(8), 1644\u20131655 (2002).","journal-title":"J. Med. Chem."},{"key":"89271_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/JVI.00061-19","volume":"93","author":"T Meng","year":"2019","unstructured":"Meng, T., Jia, Q., Wong, S. M. & Chua, K. B. In vitro and in vivo inhibition of the infectivity of human enterovirus 71 by a sulfonated food azo dye, brilliant black BN. J. Virol. 93, 17 (2019).","journal-title":"J. Virol."},{"issue":"2","key":"89271_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/v8020032","volume":"8","author":"JK Lai","year":"2016","unstructured":"Lai, J. K., Sam, I. C. & Chan, Y. F. The autophagic machinery in enterovirus infection. Viruses 8(2), 32 (2016).","journal-title":"Viruses"},{"issue":"5","key":"89271_CR16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cell.2010.03.050","volume":"141","author":"NY Hsu","year":"2010","unstructured":"Hsu, N. Y. et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141(5), 799\u2013811 (2010).","journal-title":"Cell"},{"issue":"5","key":"89271_CR17","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/JVI.02249-10","volume":"85","author":"M Arita","year":"2011","unstructured":"Arita, M. et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85(5), 2364\u20132372 (2011).","journal-title":"J. Virol."},{"issue":"11","key":"89271_CR18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bcp.2012.07.034","volume":"84","author":"L Delang","year":"2012","unstructured":"Delang, L., Paeshuyse, J. & Neyts, J. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem. Pharmacol. 84(11), 1400\u20131408 (2012).","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"89271_CR19","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.1074\/jbc.M111.312561","volume":"287","author":"N Yang","year":"2012","unstructured":"Yang, N. et al. Phosphatidylinositol 4-kinase IIIbeta is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J. Biol. Chem. 287(11), 8457\u20138467 (2012).","journal-title":"J. Biol. Chem."},{"key":"89271_CR20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3389\/fmicb.2020.01817","volume":"11","author":"X Li","year":"2020","unstructured":"Li, X. et al. Enterovirus replication organelles and inhibitors of their formation. Front. Microbiol. 11, 1817 (2020).","journal-title":"Front. Microbiol."},{"issue":"5","key":"89271_CR21","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1128\/JVI.03650-13","volume":"88","author":"CM Dorobantu","year":"2014","unstructured":"Dorobantu, C. M. et al. Recruitment of PI4KIIIbeta to coxsackievirus B3 replication organelles is independent of ACBD3, GBF1, and Arf1. J. Virol. 88(5), 2725\u20132736 (2014).","journal-title":"J. Virol."},{"issue":"10","key":"89271_CR22","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/AAC.01175-13","volume":"57","author":"HM van der Schaar","year":"2013","unstructured":"van der Schaar, H. M. et al. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIbeta. Antimicrob. Agents Chemother. 57(10), 4971\u20134981 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"89271_CR23","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1128\/AAC.00303-13","volume":"57","author":"C Spickler","year":"2013","unstructured":"Spickler, C. et al. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob. Agents Chemother. 57(7), 3358\u20133368 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"89271_CR24","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/AAC.01073-16","volume":"60","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob. Agents Chemother. 60(9), 5357\u20135367 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"89271_CR25","doi-asserted-by":"crossref","first-page":"e1005165","DOI":"10.1371\/journal.ppat.1005165","volume":"11","author":"L De Colibus","year":"2015","unstructured":"De Colibus, L. et al. Structure elucidation of coxsackievirus A16 in complex with GPP3 informs a systematic review of highly potent capsid binders to enteroviruses. PLoS Pathog. 11(10), e1005165 (2015).","journal-title":"PLoS Pathog."},{"issue":"10","key":"89271_CR26","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1128\/AAC.00946-12","volume":"56","author":"MJ Lamarche","year":"2012","unstructured":"Lamarche, M. J. et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 56(10), 5149\u20135156 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"16","key":"89271_CR27","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.bmcl.2014.07.015","volume":"24","author":"EP Keaney","year":"2014","unstructured":"Keaney, E. P. et al. 2-Alkyloxazoles as potent and selective PI4KIIIbeta inhibitors demonstrating inhibition of HCV replication. Bioorg. Med. Chem. Lett. 24(16), 3714\u20133718 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"89271_CR28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2015.10.006","volume":"124","author":"JT Kelly","year":"2015","unstructured":"Kelly, J. T. et al. Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or coxsackievirus A16. Antiviral Res. 124, 77\u201382 (2015).","journal-title":"Antiviral Res."},{"issue":"11","key":"89271_CR29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/cr.2012.129","volume":"22","author":"HM van der Schaar","year":"2012","unstructured":"van der Schaar, H. M. et al. Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication. Cell Res. 22(11), 1576\u20131592 (2012).","journal-title":"Cell Res."},{"issue":"2","key":"89271_CR30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acsinfecdis.5b00122","volume":"2","author":"M Arita","year":"2016","unstructured":"Arita, M. Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III beta inhibitor. ACS Infect. Dis. 2(2), 140\u2013148 (2016).","journal-title":"ACS Infect. Dis."},{"key":"89271_CR31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.antiviral.2017.10.006","volume":"147","author":"H Lyoo","year":"2017","unstructured":"Lyoo, H., Dorobantu, C. M., van der Schaar, H. M. & van Kuppeveld, F. J. M. Modulation of proteolytic polyprotein processing by coxsackievirus mutants resistant to inhibitors targeting phosphatidylinositol-4-kinase IIIbeta or oxysterol binding protein. Antiviral Res. 147, 86\u201390 (2017).","journal-title":"Antiviral Res."},{"key":"89271_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","volume":"159","author":"WJ Britt","year":"2018","unstructured":"Britt, W. J. & Prichard, M. N. New therapies for human cytomegalovirus infections. Antiviral Res. 159, 153\u2013174 (2018).","journal-title":"Antiviral Res."},{"issue":"11","key":"89271_CR33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: Towards a cure. Nat. Rev. Drug. Discov. 18(11), 827\u2013844 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"89271_CR34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","volume":"183","author":"U Spengler","year":"2018","unstructured":"Spengler, U. Direct antiviral agents (DAAs): A new age in the treatment of hepatitis C virus infection. Pharmacol. Ther. 183, 118\u2013126 (2018).","journal-title":"Pharmacol. Ther."},{"key":"89271_CR35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar, T. & Fordyce, M. Current status and prospects of HIV treatment. Curr. Opin. Virol. 18, 50\u201356 (2016).","journal-title":"Curr. Opin. Virol."},{"issue":"11","key":"89271_CR36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.7150\/ijbs.12996","volume":"11","author":"Q Yang","year":"2015","unstructured":"Yang, Q. et al. Studies on inhibition of proliferation of enterovirus-71 by compound YZ-LY-0. Int. J. Biol. Sci. 11(11), 1337\u20131347 (2015).","journal-title":"Int. J. Biol. Sci."},{"key":"89271_CR37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2016.09.003","volume":"134","author":"J Sun","year":"2016","unstructured":"Sun, J., Ennis, J., Turner, J. D. & Chu, J. J. Single dose of an adenovirus vectored mouse interferon-alpha protects mice from lethal EV71 challenge. Antiviral Res. 134, 207\u2013215 (2016).","journal-title":"Antiviral Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89271-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:58:41Z","timestamp":1670054321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89271-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89271-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All PI4KIII\u03b2 analogues are covered in patent\/patent applications owned by Curovir AB (JW and GA). YWT, WKY, RJWK, JJHC declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9719"}}